Skip to main content
. Author manuscript; available in PMC: 2017 Dec 13.
Published in final edited form as: Cell Metab. 2016 Oct 27;24(6):848–862. doi: 10.1016/j.cmet.2016.09.016

Figure 2. TAZ Silencing Reduces Liver Inflammation, Fibrosis, and Cell Death in FPC-Fed Mice.

Figure 2

The following parameters were measured in male C57BL/6J mice treated with AAV8-H1-shTaz or control vector and then fed the FPC diet for 16 weeks (*p < 0.05, **p < 0.01, ***p < 0.0002, mean ± SEM; n=10 mice/group):

(A) Immunoblot of TAZ in liver, with β-actin as loading control.

(B) Staining of liver sections for H&E (upper panels; Bar, 100 μm), Masson’s trichrome (Trichr) (middle panels; Bar, 100 μm), and Sirius red (Sir red) (lower panels; Bar, 500 μm).

(C) Hepatic inflammatory cells.

(D) Aniline blue- and Sirius red-positive area.

(E) Plasma ALT.

(F) TUNEL+ cells.

(G) mRNA levels of Tnfa, Mcp1, and F4/80 (Adgre1).

(H) mRNA levels of the indicated genes related to fibrosis.

(I) F4/80 immunofluorescence (red) and quantification; DAPI counterstain for nuclei is shown in bottom panels; Bar, 100 μm.

(J) α-SMA immunofluorescence (red) and quantification; DAPI counterstain for nuclei is shown in bottom panels; Bar, 100 μm.